News from io biotech A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

15 May, 2019, 13:00 BST IO Biotech Initiates Global Phase 2 Portion of Clinical Trial For T-win® Immunotherapy in Non-small Cell Lung Cancer

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies based on its proprietary T-win®...


01 May, 2019, 12:00 BST IO Biotech to Participate in Panel Discussion at 30th Annual Cancer Progress Conference in New York

IO Biotech's CEO, Mai-Britt Zocca, Ph.D., will participate in a panel discussion entitled, "IO Session I: Combination Failures & Futures: Much Ado...


01 Apr, 2019, 19:10 BST IO Biotech Presents Data on an Immunomodulatory CCL22-based Vaccine at the American Association for Cancer Research Annual Meeting 2019

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win®...


11 Jun, 2018, 06:00 BST IO Biotech Appoints Kathleen Sereda Glaub as Member of Board of Directors

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win...


12 Mar, 2018, 06:00 GMT IO Biotech enters clinical collaboration with MSD evaluating IO102 in combination with KEYTRUDA® (pembrolizumab) in first-line treatment of patients with metastatic non-small cell lung cancer

IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune modulating anti-cancer therapies, based on its proprietary T-win...


12 Oct, 2017, 14:00 BST IO Biotech Appoints Dr. Eva Ehrnrooth as Chief Medical Officer

IO Biotech, a private company developing novel immuno-oncology therapies targeting immune checkpoint inhibitory targets to treat cancer, today...